

Attorney Docket No.: 4366.220-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Schulein et al. Confirmation No: 2575

Serial No.: 10/007,521 Group Art Unit: 1652

Filed: December 5, 2001 Examiner: E. Slobodyansky

For: Endoglucanases

**CERTIFICATE OF FACSIMILE TRANSMISSION**Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner E. Slobodyansky, fax number (703) 746-5089.

Respectfully submitted,

Date: February 21, 2003



Elias J. Lambiris  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

Attorney Docket No.: 4366.220-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Schulein et al. Confirmation No: 2575

Serial No.: 10/007,521 Group Art Unit: 1652

Filed: December 5, 2001 Examiner: E. Slobodyansky

For: Endoglucanases

**AMENDMENT FEE TRANSMITTAL**Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application.

The fee for claims has been calculated as shown below:

Total:  $26 - 20 = 6 \times 18 = \$108$ Independent:  $1 - 3 = 0 \times 84 = \$0$ 

Total additional fee for claims required is \$108.

Please charge the required extension and claims fees, estimated to be \$108, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 21, 2003

  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

3  
3/4  
PATENT  
S  
B  
B33  
B34

Attorney Docket No.: 4366.220-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schulein et al. Confirmation No: 2575  
Serial No.: 10/007,521 Group Art Unit: 1652  
Filed: December 5, 2001 Examiner: E. Slobodyansky  
For: Endoglucanases

AMENDMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

Please amend the above-identified application as follows:

03/05/2003 BRIDESN 00000001 501701 10007521 108.00 CH

IN THE CLAIMS:

Please cancel claims 1, 11, 66, 84-86, 89, 91, and 97-100 without prejudice or disclaimer. Please add new claims 106-131:

106. An isolated polypeptide exhibiting endoglucanase activity, which is any of:

- (a) a polypeptide having an amino acid sequence that is at least 80% homologous with the sequence of SEQ ID NO: 12;
- (b) a polypeptide encoded by a DNA sequence which hybridizes with SEQ ID NO: 11 or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10081 under the following hybridization conditions: prehybridization and hybridization in a solution of 5 x SSC, 5 x Denhardt's solution, 0.5% SDS and 100 micrograms/ml of denatured sonicated salmon sperm DNA for 12 hours at about 45°C, followed by washing in 2 x SSC and 0.5% SDS at a temperature of 60°C, 65°C, 70°C, or 75°C; and
- (c) a fragment of the sequence of SEQ ID NO: 12 which has endoglucanase activity.

107. The polypeptide of claim 106, which has an amino acid sequence that is at least 80% homologous with the sequence of SEQ ID NO: 12.

108. The polypeptide of claim 107, which has an amino acid sequence that is at least 90% homologous with the sequence of SEQ ID NO: 12.